| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 17,441 | 18,022 | ||
| General and administrative | 5,091 | 5,451 | ||
| Impairment charge | - | 3,175 | ||
| Total operating expenses | 22,532 | 26,648 | ||
| Loss from operations | -22,532 | -26,648 | ||
| Interest income | 802 | 1,106 | ||
| Interest expense | 408 | 405 | ||
| Other income (expense), net | -6 | -2 | ||
| Net loss | -22,144 | -25,949 | ||
| Net loss per share, basic | -0.41 | -0.49 | ||
| Net loss per share, diluted | -0.41 | -0.49 | ||
| Weighted-average shares of common stock used to compute net loss per share, basic | 53,577,066 | 53,445,631 | ||
| Weighted-average shares of common stock used to compute net loss per share, diluted | 53,577,066 | 53,445,631 | ||
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)